Factory Directly Supply High Quality Semaglutide Tirzepatide CAS 910463-68-2

• CAS No.: 910463-68-2
• Formula: C187h291n45o59
• EINECS: 203-405-2
• Environmental Protection: Yes
• Certification: ISO14001
• Color: White
• Model NO.: Semaglutide
• Classification: Peptide
• Function: Promote Digestion and Appetite
• Appearance: Powder
• Transport Package: 10vilas/Kit
• Specification: 2mg, 5mg, 10mg
• Trademark: RunYan
• Origin: Zhongguo Hangzhou
• Production Capacity: 10000kg

Product Description

Product name:Semaglutide
Cas No.:910463-68-2 
Molecular formular: C187H291N45O59
Molecular weight : 4113.58
Purity: 99%
Appearance:White Crystalline Powder

Semaglutide (USAN; trade name Oze mpic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Oze mpic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production.It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat.
Product name:Semaglutide
Cas No.:910463-68-2 
Molecular formular: C187H291N45O59
Molecular weight : 4113.58
Purity: 99%
Appearance:White Crystalline Powder

Semaglutide (USAN; trade name Oze mpic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Oze mpic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production.It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat.